Trixeo Aerosphere receives positive EU CHMP opinion as first inhaled medicine with near-zero GWP
Trixeo is the first pMDI medicine in AstraZeneca’s portfolio to use the near-zero GWP propellant
Trixeo is the first pMDI medicine in AstraZeneca’s portfolio to use the near-zero GWP propellant
GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology
3SBio will receive a payment of $1.25 billion. Pfizer will also make a $100 million equity investment in 3SBio
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
Longer-term follow up in the FLAURA2 Phase III trial confirms the favourable benefit-risk profile of this combination
Godavari Biorefineries receives patent from CNIPA
The company’s largest center for medical device applications, serving the entire Asian market
IGI partners with AbbVie and grants exclusive rights to globally develop, manufacture, and commercialize ISB 2001 across North America, Europe, Japan, and Greater China
The pharmaceuticals laboratory supports North Asia with formulation development, reverse engineering, troubleshooting, and analysis for various dosage forms
Subscribe To Our Newsletter & Stay Updated